Fidelity National Financial Inc. Maintains Stake in Pfizer, Inc. (PFE)
Fidelity National Financial Inc. held its position in shares of Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the SEC. The firm owned 50,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Pfizer accounts for 0.4% of Fidelity National Financial Inc.’s holdings, making the stock its 22nd largest position. Fidelity National Financial Inc.’s holdings in Pfizer were worth $1,680,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer during the first quarter valued at $121,000. Finally, Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the last quarter. 69.09% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.045% during midday trading on Tuesday, hitting $33.485. The stock had a trading volume of 5,108,375 shares. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.18. The stock has a 50 day moving average of $33.25 and a 200-day moving average of $33.42. The company has a market cap of $199.15 billion, a P/E ratio of 24.495 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.82%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.
ILLEGAL ACTIVITY NOTICE: “Fidelity National Financial Inc. Maintains Stake in Pfizer, Inc. (PFE)” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/fidelity-national-financial-inc-maintains-stake-in-pfizer-inc-pfe/1529966.html.
PFE has been the subject of several research analyst reports. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Finally, ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $37.61.
In related news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,014 shares of company stock worth $4,062,493. 0.06% of the stock is currently owned by company insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.